Science & Education
Optimal patient care, clinical research and new therapy development require efficient and valid methods to quantify the results of biomedical imaging. QIBA accelerates the development and adoption of hardware and software standards needed to achieve accurate and reproducible quantitative results from imaging methods.
Stakeholders from the clinical research community, imaging equipment manufacturers, the pharmaceutical industry, government and medical informatics companies collaborate through QIBA to identify needs, barriers, and solutions to develop and test consistent, reliable, valid, and achievable quantitative imaging results across imaging platforms, clinical sites, and time.
For more process details please see the full Description of QIBA Process.
QIBA follows a defined, coordinated process for solutions development and adoption.
For more information, please see the QIBA Fact Sheet for reference.
Criteria for Identifying Biomarker Opportunities
Will likely result significant improvement the development, approval, or delivery care patients. The following characteristics are desirable:
An idea or program whose end goals can likely be achieved in a specific timeframe and that has a reasonable prospect of producing the expected outcomes; ideal programs are those which could result in regulatory qualification of a biomarker in three years.
Leverages preexisting resources (e.g., intellectual capital, personnel, facilities, specimens, reagents, data) wherever possible; warrants access to RSNA resources and support.
Would uniquely benefit from the multi-stakeholder composition and approach of QIBA and could be feasibly executed under its policies e.g. resulting in extension or adoption in product development among hardware, software, or imaging agents. The biomarker has the support of the stakeholder community with the organizational impetus to sustain continued efforts.